Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients.
Primary cytomegalovirus (CMV) infection is a major cause of morbidity and mortality in recipients after solid organ transplantation (SOT). Widespread and prolonged use of antiviral drugs has changed the natural course of CMV disease by delaying its onset and causing drug resistance. CMV induces a strong cellular immune response, even in immunosuppressed patients, and has developed strategies to evade this immune surveillance. This review summarizes challenges in managing CMV infection in transplant recipients and highlights current insights in the cellular immune response against CMV.
Rowshani
Ajda T
AT
Department of Internal Medicine, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, 1100 DE Amsterdam, the Netherlands. T.Rowshani@amc.uva.nl
Bemelman
Frederike J
FJ
van Leeuwen
Ester M M
EM
van Lier
René A W
RA
ten Berge
Ineke J M
IJ
D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016377:Organ Transplantation / Q000009:adverse effects*; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination; D014765:Viral Vaccines / Q000276:immunology
D014765:Viral Vaccines